New vaccine aims to block malaria transmission in mosquitoes
NCT ID NCT05913973
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new vaccine designed to stop the malaria parasite from spreading from people to mosquitoes. 105 healthy adults received three doses of the vaccine over several months. The main goal was to check if the vaccine is safe and triggers an immune response. Participants were not exposed to malaria during the study.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill make your blood deadly to malaria mosquitoes?
- Can a new vaccine stop malaria in its tracks?
- Can a new malaria vaccine slash childhood cases? a massive real-world test seeks answers.
- One shot, six months of malaria shield? a new trial tests a powerful antibody in children
- School health rooms and trained teachers: a new hope for Zambia's children?
- Experimental malaria vaccine aims to block parasite growth